Creative Medical Technology (NASDAQ:CELZ) Issues Earnings Results, Beats Expectations By $0.01 EPS

Creative Medical Technology (NASDAQ:CELZ) announced its quarterly earnings results on Friday. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.01, Zacks reports.

Creative Medical Technology Stock Up 0.9%

Shares of Creative Medical Technology stock traded up $0.02 during trading on Friday, reaching $2.31. 68,109 shares of the stock were exchanged, compared to its average volume of 69,840. The firm has a market cap of $8.54 million, a price-to-earnings ratio of -0.89 and a beta of 1.87. Creative Medical Technology has a 1 year low of $1.50 and a 1 year high of $6.25. The stock’s fifty day moving average is $2.05 and its 200 day moving average is $2.32.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Creative Medical Technology stock. Jane Street Group LLC acquired a new position in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 30,205 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned about 1.17% of Creative Medical Technology as of its most recent filing with the SEC. 1.42% of the stock is owned by hedge funds and other institutional investors.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.